ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs

Overview

Journal Nat Commun

Specialty Biology

Date 2023 Feb 22

PMID 36813801

Authors

Bing He

Yao Xiao

Haodong Liang

Qianhui Huang

Yuheng Du

Yijun Li

David Garmire

Duxin Sun

Lana X Garmire

Affiliations

Soon will be listed here.

Abstract

Single-cell RNA sequencing technology has enabled in-depth analysis of intercellular heterogeneity in various diseases. However, its full potential for precision medicine has yet to be reached. Towards this, we propose A Single-cell Guided Pipeline to Aid Repurposing of Drugs (ASGARD) that defines a drug score to recommend drugs by considering all cell clusters to address the intercellular heterogeneity within each patient. ASGARD shows significantly better average accuracy on single-drug therapy compared to two bulk-cell-based drug repurposing methods. We also demonstrated that it performs considerably better than other cell cluster-level predicting methods. In addition, we validate ASGARD using the drug response prediction method TRANSACT with Triple-Negative-Breast-Cancer patient samples. We find that many top-ranked drugs are either approved by the Food and Drug Administration or in clinical trials treating corresponding diseases. In conclusion, ASGARD is a promising drug repurposing recommendation tool guided by single-cell RNA-seq for personalized medicine. ASGARD is free for educational use at https://github.com/lanagarmire/ASGARD .

Citing Articles

Single-cell RNA-seq data have prevalent blood contamination but can be rescued by Originator, a computational tool separating single-cell RNA-seq by genetic and contextual information.

Unjitwattana T, Huang Q, Yang Y, Tao L, Yang Y, Zhou M Genome Biol. 2025; 26(1):52.

PMID: 40069819 PMC: 11895284. DOI: 10.1186/s13059-025-03495-9.

A comprehensive analysis to reveal the underlying molecular mechanisms of natural killer cell in thyroid carcinoma based on single-cell RNA sequencing data.

Li X, Wang K, Liu J, Li Y Discov Oncol. 2025; 16(1):44.

PMID: 39808350 PMC: 11732816. DOI: 10.1007/s12672-025-01779-x.

Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial Teams.

Cosgrove P, Bild A, Dellinger T, Badie B, Portnow J, Nath A J Clin Med. 2025; 13(24.

PMID: 39768430 PMC: 11677125. DOI: 10.3390/jcm13247507.

Pan-cancer drivers of metastasis.

Lusby R, Demirdizen E, Inayatullah M, Kundu P, Maiques O, Zhang Z Mol Cancer. 2025; 24(1):2.

PMID: 39748426 PMC: 11697158. DOI: 10.1186/s12943-024-02182-w.

DrugReSC: targeting disease-critical cell subpopulations with single-cell transcriptomic data for drug repurposing in cancer.

Liu C, Zhang Y, Liang Y, Zhang T, Wang G Brief Bioinform. 2024; 25(6).

PMID: 39350337 PMC: 11442150. DOI: 10.1093/bib/bbae490.

References

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S . Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-21. DOI: 10.1056/NEJMoa1300874. View

McCarthy D, Chen Y, Smyth G . Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012; 40(10):4288-97. PMC: 3378882. DOI: 10.1093/nar/gks042. View

Ling B, Watt K, Banerjee S, Newsted D, Truesdell P, Adams J . A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models. Oncotarget. 2017; 8(35):58372-58385. PMC: 5601659. DOI: 10.18632/oncotarget.17702. View

Sasidharan Nair V, Toor S, Ali B, Elkord E . Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opin Ther Targets. 2018; 22(6):547-557. DOI: 10.1080/14728222.2018.1471137. View

Wong W . Tretinoin in the treatment of acute promyelocytic leukemia. Cancer Pract. 1996; 4(4):220-3. View

Merino D, Weber T, Serrano A, Vaillant F, Liu K, Pal B . Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nat Commun. 2019; 10(1):766. PMC: 6377663. DOI: 10.1038/s41467-019-08595-2. View

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

Huang Q, Liu Y, Du Y, Garmire L . Evaluation of Cell Type Annotation R Packages on Single-cell RNA-seq Data. Genomics Proteomics Bioinformatics. 2020; 19(2):267-281. PMC: 8602772. DOI: 10.1016/j.gpb.2020.07.004. View

Lahnemann D, Koster J, Szczurek E, McCarthy D, Hicks S, Robinson M . Eleven grand challenges in single-cell data science. Genome Biol. 2020; 21(1):31. PMC: 7007675. DOI: 10.1186/s13059-020-1926-6. View

10.

Yoon S, Baik B, Park T, Nam D . Powerful p-value combination methods to detect incomplete association. Sci Rep. 2021; 11(1):6980. PMC: 7997958. DOI: 10.1038/s41598-021-86465-y. View

11.

Mourragui S, Loog M, Vis D, Moore K, Manjon A, van de Wiel M . Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning. Proc Natl Acad Sci U S A. 2021; 118(49). PMC: 8670522. DOI: 10.1073/pnas.2106682118. View

12.

Ayoub N, Al-Shami K, Alqudah M, Mhaidat N . Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. Onco Targets Ther. 2017; 10:4869-4883. PMC: 5634371. DOI: 10.2147/OTT.S148604. View

13.

Sominsky L, Walker D, Spencer S . One size does not fit all - Patterns of vulnerability and resilience in the COVID-19 pandemic and why heterogeneity of disease matters. Brain Behav Immun. 2020; 87:1-3. PMC: 7102615. DOI: 10.1016/j.bbi.2020.03.016. View

14.

Chan J, Wang X, Turner J, Baldwin N, Gu J . Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. Bioinformatics. 2019; 35(16):2818-2826. PMC: 6691331. DOI: 10.1093/bioinformatics/btz006. View

15.

Aran D, Looney A, Liu L, Wu E, Fong V, Hsu A . Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019; 20(2):163-172. PMC: 6340744. DOI: 10.1038/s41590-018-0276-y. View

16.

Ching T, Huang S, Garmire L . Power analysis and sample size estimation for RNA-Seq differential expression. RNA. 2014; 20(11):1684-96. PMC: 4201821. DOI: 10.1261/rna.046011.114. View

17.

Chai J, Jung B, Hong S . Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update. Korean J Parasitol. 2021; 59(3):189-225. PMC: 8255490. DOI: 10.3347/kjp.2021.59.3.189. View

18.

Jing B, Jin J, Xiang R, Liu M, Yang L, Tong Y . Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition. Cell Death Dis. 2018; 9(6):589. PMC: 5964102. DOI: 10.1038/s41419-018-0679-6. View

19.

Siddiqi T, Frankel P, Beumer J, Kiesel B, Christner S, Ruel C . Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma. 2019; 61(2):309-317. PMC: 6982547. DOI: 10.1080/10428194.2019.1672052. View

20.

Nagata K, Ohtani K, Nakamura M, Sugamura K . Activation of endogenous c-fos proto-oncogene expression by human T-cell leukemia virus type I-encoded p40tax protein in the human T-cell line, Jurkat. J Virol. 1989; 63(8):3220-6. PMC: 250891. DOI: 10.1128/JVI.63.8.3220-3226.1989. View